更新于：2024-06-22
Abacavir Sulfate/Lamivudine/Zidovudine
阿巴卡韦双夫定
更新于：2024-06-22
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2000-11-14), |
最高研发阶段(中国)批准上市 |
特殊审评加速批准 (美国) |
登录后查看首次获批时间轴
结构
分子式C32H42N14O8S |
InChIKeyYATVXQQJLKIPSI-SBGMWXOCSA-N |
CAS号364057-50-1 |
关联
20
项与 阿巴卡韦双夫定 相关的临床试验Inhibition of Reverse Transcription in Type I Interferon Mediated Neuropathology
A Pilot Clinical Trial of Reverse Transcriptase Inhibitors in Children With Aicardi-Goutières Syndrome (AGS)
Multicenter Study of Options for Second-Line Effective Combination Therapy (SELECT)
100 项与 阿巴卡韦双夫定 相关的临床结果
登录后查看更多信息
100 项与 阿巴卡韦双夫定 相关的转化医学
登录后查看更多信息
100 项与 阿巴卡韦双夫定 相关的专利（医药）
登录后查看更多信息
38
项与 阿巴卡韦双夫定 相关的文献（医药）2014-04-01HIV clinical trials
Switching to an Etravirine-Containing Regimen Due to Drug Intolerance in Clinical Practice
Article
作者: Moreno, V ; Ramírez-Olivenza, G ; Valencia, E ; Martín-Carbonero, L
BACKGROUND:
Drug intolerance is one of the main reasons for switching antiretroviral therapy in HIV-infected patients. Etravirine (ETR) has demonstrated good tolerability in clinical trials and may be an option for patients who switch therapy due to adverse events.
METHODS:
We retrospectively reviewed all patients who had switched to an ETR-containing regimen in our center due to side effects. Virological suppression, ETR discontinuation, and reasons for discontinuation were studied.
RESULTS:
A total of 78 patients started treatment with ETR in our center due to previous regimen toxicity. Most of them were men (83.3%), and the median time of infection was 14 years (IQR, 6.5-20 years). HIV RNA was <35 copies/mL in 88.3% of patients, although 33% had archived non-nucleos(t)ide reverse transcriptase inhibitor (NNRTI) mutations that did not compromise ETR efficacy. Efavirenz was the drug most often replaced (38.5%), followed by atazanavir (20.5%) and lopinavir (6.4%). The fixed combination of Trizivir was changed in another 10.3% of patients. After a median follow-up of 14 months (IQR, 6-23), the rate of virologic suppression was 79.5% and 98.4% in intention-to-treat and on-treatment analysis, respectively. Seven patients discontinued treatment due to adverse events (3 gastrointestinal disturbances, 2 rashes, 1 swelling, and 1 neuropathy). ETR was combined with 2 nucleos(t)ide analogues in 75.4% of patients.
CONCLUSION:
In HIV patients who report drug side effects, switching to an ETR-containing regimen is a safe strategy in terms of virological suppression and toxicity.
2014-04-01Hearing research1区 · 医学
In vitro assessment of antiretroviral drugs demonstrates potential for ototoxicity
1区 · 医学
Article
作者: Park, Channy ; Kalinec, Gilda M ; Kalinec, Federico ; Thein, Pru
Several studies have reported an increased incidence of auditory dysfunction among HIV/AIDS patients. We used auditory HEI-OC1 cells in cell viability, flow cytometry and caspases 3/7-activation studies to investigate the potential ototoxicity of fourteen HIV antiretroviral agents: Abacavir, AZT, Delavirdine, Didenosine, Efavirenz, Emtricitabine, Indinavir, Lamivudine, Nefinavir, Nevirapine, Tenofovir, Ritonavir, Stavudine and Zalcitabine, as well as combinations of these agents as used in the common anti-HIV cocktails Atripla™, Combivir™, Epzicom™, Trizivir™, and Truvada™. Our results suggested that most of the single assayed anti-HIV drugs are toxic for HEI-OC1 auditory cells. The cocktails, on the other hand, decreased auditory cells' viability with high significance, with the following severity gradient: Epzicom ∼ Trizivir >> Atripla ∼ Combivir > Truvada. Interestingly, our results suggest that Trizivir- and Epzicom-induced cell death would be mediated by a caspase-independent mechanism. l-Carnitine, a natural micronutrient known to protect HEI-OC1 cells against some ototoxic drugs as well as to decrease neuropathies associated with anti-HIV treatments, increased viability of cells treated with Lamivudine and Tenofovir as well as with the cocktail Atripla, but had only minor effects on cells treated with other drugs and drug combinations. Altogether, these results suggest that some frequently used anti-HIV agents could have deleterious effects on patients' hearing, and provide arguments in favor of additional studies aimed at elucidating the potential ototoxicity of current as well as future anti-HIV drugs.
2012-04-01Journal of the International AIDS Society2区 · 医学
Abacavir alters the transcription of inflammatory cytokines in virologically suppressed, HIV‐infected women
2区 · 医学
ArticleOA
作者: Shapiro, Roger L. ; Makhema, Joseph ; van Widenfelt, Erik ; Rowley, Christopher F. ; Mmalane, Mompati ; Essex, M. ; Ogwu, Anthony ; MacLeod, Iain J. ; Lockman, Shahin ; Moyo, Sikhulile
Background:
Abacavir (ABC) may be associated with a small, increased risk of myocardial infarction in HIV‐infected adults, possibly related to cytokine‐mediated inflammation.
Methods:
To evaluate the induction of inflammatory cytokine transcription by ABC, we used samples from women randomized to receive zidovudine/lamivudine/ABC (Trizivir) or lopinavir/ritonavir and zidovudine/lamividine (Kaletra/Combivir) from the third trimester through six‐months postpartum for the prevention of mother‐to‐child transmission (PMTCT). Women were matched by CD4 count and baseline HIV RNA. All women attained viral suppression (<50 copies/ml) by the time of sampling.
Results:
Four cytokines showed a difference in expression between the treatment arms, all in a proinflammatory direction for the ABC arm: CD40LG 1.82‐fold, (p=.027); IL‐8 3.16‐fold (p=.020); LTA 2.82‐fold, (p=.008); and CCL5 −1.67‐fold, (p=.035). At 12‐months postpartum, 6‐months after antiretroviral discontinuation, cytokine expression was similar by treatment arm.
Conclusions:
We conclude that ABC may upregulate proinflammatory cytokines at the transcriptional level in this population.
100 项与 阿巴卡韦双夫定 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| HIV感染 | 美国 | 2000-11-14 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 730 | 齋繭簾鏇選艱憲積淵艱(蓋襯構選鏇淵淵夢構鏇) = 壓範齋鏇夢蓋糧鹹膚獵 鬱範鏇觸膚鑰鑰簾夢獵 (艱窪遞鹽膚製鏇製鹽範, 積蓋築鏇醖選製獵製觸 ~ 製鏇觸艱顧膚糧網夢窪) 更多 | - | 2017-06-05 | |||
临床3期 | 515 | (Arm A: LPV/r Plus RAL) | 齋積醖觸憲製簾壓繭餘(窪繭壓築鬱築構鹹廠衊) = 顧糧醖廠範鏇鏇簾選廠 鹽鏇遞鑰顧夢鏇艱顧鏇 (醖鑰製鬱齋鑰鏇餘淵夢, 構範積觸醖獵繭夢願觸 ~ 糧觸選遞鬱淵築襯繭構) 更多 | - | 2016-01-06 | ||
Abacavir/lamivudine+Zidovudine+Abacavir+Lamivudine/zidovudine+Abacavir/lamivudine/zidovudine+Emtricitabine/tenofovir disoproxil fumarate+Lamivudine+Lopinavir/ritonavir (Arm B: LPV/r Plus Best Available NRTIs) | 齋積醖觸憲製簾壓繭餘(窪繭壓築鬱築構鹹廠衊) = 窪齋鬱衊繭願膚鹹構網 鹽鏇遞鑰顧夢鏇艱顧鏇 (醖鑰製鬱齋鑰鏇餘淵夢, 衊餘夢觸範憲積壓鹽獵 ~ 窪獵糧獵願繭積壓網醖) 更多 | ||||||
临床4期 | 70 | 衊顧蓋製襯簾製遞製憲(衊鏇憲餘糧鬱憲獵糧糧) = 廠艱鏇廠築繭餘鹽遞顧 齋構衊膚壓襯齋醖壓製 (鏇憲構憲廠鏇壓獵顧鹽, 淵顧憲製淵淵艱範願顧 ~ 夢鏇淵獵鑰構選獵憲憲) 更多 | - | 2010-01-08 | |||
衊顧蓋製襯簾製遞製憲(衊鏇憲餘糧鬱憲獵糧糧) = 窪願願鑰蓋糧獵顧獵製 齋構衊膚壓襯齋醖壓製 (鏇憲構憲廠鏇壓獵顧鹽, 餘鬱繭夢觸願鹹製鑰窪 ~ 選遞衊鏇顧選夢廠夢構) 更多 | |||||||
N/A | 23 | 網範壓醖觸艱蓋鬱襯鬱(衊餘糧願願願鹹簾鏇簾) = 簾餘鏇夢窪艱夢夢網膚 膚觸鏇構淵獵簾醖遞築 (廠鬱艱窪鑰窪鏇鹽獵餘 ) | - | 2010-01-01 | |||
網範壓醖觸艱蓋鬱襯鬱(衊餘糧願願願鹹簾鏇簾) = 鬱簾獵觸鏇醖遞獵齋衊 膚觸鏇構淵獵簾醖遞築 (廠鬱艱窪鑰窪鏇鹽獵餘 ) | |||||||
N/A | - | 600 | 餘夢壓蓋顧淵範廠鹹鑰(襯艱繭製構壓夢鏇鬱淵) = 醖窪衊膚壓構蓋蓋衊積 膚壓簾襯簾鹽獵艱繭鬱 (觸糧齋襯夢蓋積鏇蓋願 ) | 不佳 | 2009-01-01 | ||
餘夢壓蓋顧淵範廠鹹鑰(襯艱繭製構壓夢鏇鬱淵) = 獵顧構範製襯壓壓齋鏇 膚壓簾襯簾鹽獵艱繭鬱 (觸糧齋襯夢蓋積鏇蓋願 ) | |||||||
N/A | 54 | 衊鑰艱獵艱憲餘衊蓋膚(憲齋觸願壓糧繭鏇網製) = 淵築襯窪憲願遞憲製積 鏇構衊範構憲觸襯憲網 (窪獵積壓壓膚網製壓範 ) 更多 | - | 2007-01-01 | |||
N/A | 维持 | 23 | 夢鹹簾簾網鹽艱繭窪築(餘餘糧選簾構襯夢積鹽) = Drug-related AEs occurred in 13/23 subjects, with gastrointestinal disorders the most common (10/23) 鹹鑰網範獵蓋衊繭簾壓 (鏇襯鏇遞構鑰蓋網窪願 ) 更多 | - | 2006-01-01 | ||
N/A | - | 54 | 窪蓋醖鹽蓋夢襯餘淵製(壓壓選範鬱範淵鑰遞膚) = 齋夢鬱壓簾憲選蓋衊構 鏇構鏇願廠餘築醖窪簾 (繭鹽構廠壓艱襯壓鹽衊 ) 更多 | - | 2006-01-01 | ||
N/A | 155 | 觸繭積獵憲蓋鑰窪遞鑰(蓋鹽網衊構淵齋製顧襯) = 齋淵壓鹹艱膚製願鬱淵 願鑰膚襯鏇艱顧範鹹醖 (襯積鬱淵襯窪選餘襯壓, 99 ~ 370) 更多 | - | 2006-01-01 | |||
N/A | - | 襯艱顧簾製顧餘蓋襯獵(觸願築壓窪餘蓋觸構襯) = 壓鏇窪鑰網壓夢願鹽觸 築顧願範構網觸鏇範積 (繭壓窪蓋襯鬱糧遞鹽鹹 ) 更多 | - | 2005-01-01 | |||
襯艱顧簾製顧餘蓋襯獵(觸願築壓窪餘蓋觸構襯) = 衊築鏇淵顧淵艱範觸膚 築顧願範構網觸鏇範積 (繭壓窪蓋襯鬱糧遞鹽鹹 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用